4basebio AG reaffirms earning guidance for the fiscal year 2020. For the fiscal year 2020, The company expects operational cash burn for 2020, excluding expenses relating to the Abcam transaction, is expected to be between EUR 2.5 million to EUR 3.5 million with revenues between EUR 0.5 million and EUR 1.0 million.